Skip to main content
Article thumbnail
Location of Repository

Towards a sustainable system of drug development

By Ellen H.M. Moors, Adam F. Cohen and Huub Schellekens


Drug development has become the exclusive activity of large pharmaceutical companies. However, the output of new drugs has been decreasing for the past decade and the prices of new drugs have risen steadily, leading to access problems for many patients. By analyzing the history of drug development and the pharmaceutical industry, we identified the main factors causing this system failure. Although many solutions have been suggested to fix the drug development system, we believe that a combination of reforms of the regulatory and patent systems is necessary to make drug development sustainable. These reforms must be combined with a larger, open-access role for public research institutes in the discovery, clinical evaluation and safety evaluation of new drugs

Topics: generic drug, new drug, cost effectiveness analysis, drug approval, drug development, drug industry, drug manufacture, drug marketing, drug safety, drug screening, drug surveillance program, human, industrial production, mergers and acquisitions, patent, public-private partnership, reimbursement, review
Year: 2014
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.